KASINGER JAMES R. 4

What Happened

• James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics (CRSP), had restricted stock units (RSUs) vest on Feb 18, 2026 and converted/received 3,825 shares. Following the vesting, he sold 2,112 shares in an open‑market transaction on Feb 19, 2026 at $52.58 per share for proceeds of $111,049. The sale was used to satisfy tax withholding obligations and was not a discretionary trade.

Key Details

• Vesting / conversion (code M): 3,825 RSU shares converted to common shares on 2026‑02‑18 (per filing).
• Sale (code S): 2,112 shares sold on 2026‑02‑19 at $52.58 per share; total proceeds $111,049.
• Footnotes: F1 notes each RSU equals one share; F2 states the sale represented shares sold to cover tax withholding under the company RSU Settlement Policy (mandated, not discretionary); F3 describes the original RSU grant (Feb 18, 2022) and quarterly vesting schedule, with this being the final quarter vesting on Feb 18, 2026.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Filing: Form 4 filed 2026‑02‑20 reporting the Feb 18–19, 2026 transactions (no late‑filing indication in the excerpt).

Context

• The M code indicates a conversion/exercise of a derivative (here, RSU vesting). The sale of shares immediately after vesting was a routine, mandatory sell-to-cover for taxes (a form of cashless settlement), and should not be interpreted as a discretionary sell signal about company prospects. Purchases (if any) tend to be more informative about insider sentiment than mandatory withholding sales.